Form 4: Replimune Group Director Acquires Stock Options
SEC Form 4 Filing
Madhavan Balachandran, a director at Replimune Group, Inc., acquired stock options for 32,000 shares on April 1, 2025.
Summary
- On April 1, 2025, Madhavan Balachandran, a director of Replimune Group, Inc., acquired stock options for 32,000 shares.
- The exercise price of the stock options is $8.40.
- The options vest entirely on April 1, 2026, and expire on April 1, 2035.
- Following the transaction, Balachandran directly owns derivative securities for 32,000 shares.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding stock option grants, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of transaction: Director acquired stock options. |
| 04/01/2026 | Vesting date for the stock options. |
| 04/01/2035 | Expiration date for the stock options. |
| 04/03/2025 | Date of Form 4 filing. |
Keywords
stock options, Form 4, Replimune Group, director, beneficial ownership, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.